Solid Biosciences Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Solid Biosciences Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $135.37M, a 4329.55% increase year-over-year.
- Solid Biosciences Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $3.10M.
- Solid Biosciences Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $5.36M, a 110.99% increase year-over-year.
- Solid Biosciences Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $3.06M.
- Solid Biosciences Inc. stock issued during period, value, new issues for fiscal 2025 was $135.37M, a 636.93% increase from fiscal 2024.
- Solid Biosciences Inc. stock issued during period, value, new issues for fiscal 2024 was $18.37M, a 517.65% increase from fiscal 2023.
- Solid Biosciences Inc. stock issued during period, value, new issues for fiscal 2023 was $2.97M, a 95.90% decline from fiscal 2022.
- Solid Biosciences Inc. stock issued during period, value, new issues for fiscal 2022 was $72.55M, a 46.21% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $135.37M 10-K · filed 2026-03-19 | |
| 2025-03-31 | $135.37M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $18.37M 10-K · filed 2025-03-06 | |
| 2024-09-30 | $3.10M 10-Q · filed 2024-11-06 | $11.95M derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-06-30 | $5.36M 10-Q · filed 2024-11-06 | $8.85M derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-03-31 | $3.06M 10-Q · filed 2025-05-15 | $6.03M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $2.97M 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | |
| 2023-06-30 | $2.54M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $72.55M 10-K · filed 2024-03-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $134.88M 10-K · filed 2024-03-13 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | |
| 2021-03-31 | $134.88M 10-Q · filed 2022-04-27 | |
| 2020-12-31 | $109.42M 10-K · filed 2023-03-23 | |
| 2019-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $47.22M 10-K · filed 2022-03-14 |
| 2019-09-30 | $47.25M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $129.10M 10-K · filed 2021-03-15 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | |
| 2018-03-31 | $129.10M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |